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Despite being described as the safest antiepileptic drug of first
choice the presented literature data are much varied as far as dog
blood serum biochemical parameters are considered. The aim of this
study was to investigate the effect of phenobarbitone at different per os
doses on the values of selected blood serum biochemical parameters
in dogs during both short and long term application. The study was
conducted on 30 dogs of different races, both sexes, ranging from 2 to
8 years of age. A total of 15 healthy and 15 dogs suffering from
idiophatic epilepsy were observed. During the short term per os
application of phenobarbitone (given at 3 week intervals) to the healty
population in varied doseses a statistically significant increase in ALT
and AP was recorded. Application of 16 mg/kg/day of phenobarbitone
to the healthy population during 14 days resulted in a significant
increase of ALT ans AP. This increase was dependant on the duration of
the treatment. During chronic application of phenobarbitone to dogs
suffering from idiopathic epilepsy a significant increase in values of AP
and ALT depending on the given dose was recorded. In two of the
studied epileptic dogs treated with high therapeutic doses of
phenobarbitone clinical signs of hepatotoxicity were recorded.
Hepatotoxicity resulted in decreased albumin and total protein
concentrations, as well as increased blood serum total bilirubin, AST,
ALP and AP.
The obtained results indicate that a long term application of
phenobarbitone at high therapeutic doses can cause hepatotoxicity.
However, there was no relationship between phenobarbitone dosage
and duration of therapy and blood glucose, urea, creatinine, total
proteins, albumins, total bilirubin, triglycerides and cholesterol.
Key words: blood serum, dogs, epilepsy, hepatotoxicity,
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INTRODUCTION
Epilepsy is the most common neurological disorder in dogs. Irrespective of
the cause epilepsy is treated with antiepileptic drugs. Despite being often
described as an "old fashioned" drug phenobarbitone is still the drug of first
choice in the treatment of epilepsy in dogs (Lane and Bunch. 1990; McNamara,
1996; Rambeck, 2001; Berendt, 2002). The anticonvulsive effect of this drug is
achieved when its blood serum concentration reaches 15 µg/mL - 45 µg/mL
(65 mmol/L - 193 mmol/L) (Farnbach, 1984; Lane and Bunch, 1990; Sisson, 1990;
Boothe, 1996). Some authors report the best therapeutic results when blood
serum phenobarbitone concentration is 20 µg/mL - 40 µg/mL (Frey, 1989;
LeCouter, 1995; Podell, 1996).
Despite the fact of being a safe drug the data published up to now report that
therapy with phenobarbitone can cause a number of changes in the biochemical
blood serum profile. A number of studies carried out on dogs (Dayrell-Hart et al.,
1991; Chauvet et al., 1995; Foster et al., 2000; Müller et al., 2000; Aitken et al.,
2003; Gaskill et al., 2004; Gaskill et al., 2005) report increased activities of alanine
transaminase (ALT) and alkaline phosphatase (AP). Increased ALT and AP
activities were mainly recorded in patients who did not display clinical signs of
hepatopaties. Similar results were reported for humans, however this was not an
indication for changing the drug or its dose (Lippi et al., 2008). Contrary to these
findings are those reported by Daryell and Hart (2008) who recorded increased
AP and ALT activities accompanied by signs of hepatotoxicity as the result of
phenobarbitone treatment. Dogs suffering from phenobarbitone iatrogenic
hepatotoxicity displayed clinical signs such as disorientation, confusion, anorexy,
icterus and ascites.
There are some controversies if phenobarbitone treatment can cause
increased AST activity as a consequence of enzyme induction. AST can increase
as a result of phenobarbitone treatment in humans (Verma and Haidukewych,
1994) and rats (Attia and Aref, 1991). Despite the fact that increased AST activity
caused by increased enzyme induction in dogs is possible (center, 1995) a study
on Beagle dogs treated with high phenobarbitone doses for over 3 weeks
(Tettenborn et al., 1973) and a study on 12 dogs of different breeds treated with
5 mg/kg/day for 27 weeks did not confirm this hypothesis (Müller et al., 2000).
A transient statistically significant increase in albumin and total protein
concentration during epilepsy treatment with phenobarbitone in a dose of
10 mg/kg/day for 27 weeks was reported by Müller et al. (2000). Similar results
were obtained in a study on 95 dogs treated with phenobarbitone doses in a
range from less than 2 mg/kg/day up to over 10 mg/kg/day (Aitken et al., 2003).
However, in a trial carried out on 10 dogs receiving phenobarbitone 6 mg/kg/day
during 12 weeks there was no statistically significant change in total protein and
albumin blood concentrations compared to the untreated control (Foster et al.,
2000). Statistically significant differences in albumin and total protein
concentrations were not recorded in a study on 10 dogs treated with
phenobarbitone in doses from 3.9 mg/kg/day to 14.4 mg/kg/day (Foster et al.,
2000).
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Literature data on the effects of phenobarbitone on serum bilirubin
concentration indicate that the concentration of bilirubin does not change
depending on phenobarbitone concentration (Foster et al., 2000) or duration of
treatment (Chauvet, 1995). However, an increased bilirubin concentration above
referent values was recorded in dogs suffering from hepatotoxicity as a
consequence of phenobarbitone treatment (Dayrell-Hart et al., 1991).
The aim of this research was to study the effects of different per os
therapeutic phenobarbitone doses on biochemical blood parameters in order to
establish if the duration of the treatment affects enzyme activities in treated dogs.
MATERIAL AND METHODS
Animals: The experiment was carried out on 30 dogs allotted into two
experimental groups. The first group of 15 healthy dogs was treated with per os
phenobarbitone at different therapeutic doses and the second group consisted of
dogs suffering idiopathic epilepsy treated with phenobarbitone.
The first experimental group: The first group consisted of 15 male healthy
experimental mongrels, 2-8 years of age and body weight 10.3 – 25 kg. At the start
of the experiment the dogs were clinically examined and treated twice with
antihelmintic Cestal plus (CEVA / Phylaxia). The accomodation period was 21
days, during which the dogs were vaccinated against infective diseases with
Duramune DA2LP + Pi (Fort Dodge Laboratories, Iowa, USA) and Rabicel
(Veterinarski zavod A. D., Zemun). The experiment was set in such a way that
dogs received phenobarbitone at doses which were changed at three week
intervals. Blood samples were taken each time the dose was changed and blood
cell count, serum biochemistry and phenobarbitone concentration were
determined. The experiment took place for 9 weeks and the pr os applied doses
were 2 mg/kg/12h, 5 mg/kg/12h and 8 mg/kg/12h. Thereon, phenobarbitone was
applied to the same dogs in an average dose of 8 mg/kg/12h for 11 weeks (a total
of 14 weeks with this dose). During this period, starting from week four, blood
samples were taken weekly and blood cell count, serum biochemistry and
phenobarbitone concentration were determined.
The second experimental group: The second experimental group consisted
of 15 mixed breed dogs of both sexes (4 females and 11 males), body mass 3.5 –
49 kg and 2 to 4.5 years of age, all of which were diagnosed idiopathic epilepsy.
The dogs were treated with phenobarbitone from one to five years. The females
were ovariohysterectomized and the males were left intact. The starting
phenobarbitone dose for this group was 2 mg/kg/12h per os. As long as
phenobarbitone serum concentration was smaller than adviced the per os dose
was not changed until sezures developed, and this was so three weeks after the
start of the treatment. During the trial the dose of the drug was increased only if the
frequency of the sezures was unacceptable. Prior to each dose change a
thorough clinical and biochemical examination of the dog was carried out.
Blood samples. Blood samples were taken by sterile venepunction of the v.
cephalicae antebrachi with a 0.9 gauge needle. The prepared plasma and serum
blood samples were analyzed on the same day on which they were taken with the
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exeption of serum samples from the first group of dogs. These samples were
frozen at -20oC and phenobarbitone determination was done at monthly intervals.
Serum samples taken from the second group of animals (dogs suffering from
idiopathic epilepsy) phenobarbitone concentration was determined in fresh
samples with no previous freezing. The tested biochemical parameters were:
glucose, urea, creatinine, triglycerides, cholesterol, total proteins, albumin, total
bilirubin concentrations, and AST, AP, ALT enzyme activities. The biochemical
panel was determined on an automatic analyzer Basic - Sekomam (France) with
J.T. Baker (Holland) reagents. The serum phenobarbitone concentration was
measured at the Deparment of Toxicological Chemistry, Center for Poison Control
at the Military Medical Academy (Belgrade) by HPLC at 254 nm.
Analysis. Statistical data analysis was completed with the Statistica 5.0
software. Results are given by descriptive statistical methods (mean value SV,
standard deviation SD, and standard error SE). Comparison between groups was
done with Student's t-test for a small sample and the multifactorial analysis by
MANOVA (multifactorial variance analysis). Statistical significance was accepted
at the level of p<0.05.
RESULTS AND DISCUSSION
On analyses of the results in the first group of healthy dogs three weeks after
the start of phenobarbitone therapy in a dose of 4 mg/kg/day (2 mg/kg/12h) a
statistically significant increase was measured only for AP. Within the same group
of experimental dogs, after the first three weeks of treatment with 10 mg/kg/day
(5 mg/kg/12h) phenobarbitone, a statistically significant increase was measured
both for AP and ALT. Studies on the effect of a 14 weeks phenobarbitone treatment
on blood biochemical parameters of healthy dogs at an average per os dose of
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** ** ** ** **
** **
** **
Figure 1. Average AP activities (X ± SD) in the first group of dogs treated with 16 mg/kg/
day phenobarbitone per os for 14 weeks
**Very significant difference (p<0.01) compared to measurements before treatment
16 mg/kg/day (starting at 4 weeks, at weekly intervals) have shown a significant
increase in AP (Figure 1) and ALT activities (Figure 2).
Results have shown ALT activities increased when the phenobarbitone dose
reached 10 mg/kg/day and reached a high statistical significance (p<0.01) at
16 mg/kg/day. During the 14 weeks of phenobarbitone treatment ALT activity
increased throughout the trial which resulted with a statistically significant
increase by the end of the trial (Figure 2).
The group of dogs suffering from idiopathic epilepsy (second group) and
receiving phenobarbitone at doses of 4 mg/kg/day and 6 mg/kg/day a statistically
significant increase of AP was measured. Per os treatment with 8 mg/kg/day
phenobarbitone resulted in an even more dramatic increase in AP activity (Figure
3) accompanied with increased ALT activity (Figure 4). When the unadequate
response to 10 mg/kg/day phenobarbitone antiepileptic therapy was observed
the measured ALT and AP activities were significantly higher. At the average dose
of 13 mg/kg/day a significant (p<0.05) decrease in albumin and total protein
concentrations was measured, as well as a significant (p<0.01) increase in ALT
and AP activities. At a higher therapeutic dose of 16 mg/kg/day when an
unadequate effect was recorded a significant decrease (p<0.05) of albumin and
total proteins and increased values for total bilirubin (Figure 8) were measured.
The same phenobarbitone dose induced a statistically significant increase in ALT
and AP activities.
In the second group of dogs suffering from idiopathic epilepsy ALT activities
increased depending on phenobarbitone dose. In this group significantly higher
(p<0.05) ALT activities were measured at phenobarbitone doses of 8 and
10 mg/kg/day and recorded values were even higher (p<0.01) for
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Figure 2. Average ALT activities (X ± SD) in the first group of dogs treated with 16 mg/kg/
day phenobarbitone per os for 14 weeks
**Very significant difference (p<0.01) compared to measurements before treatment
phenobarbitone doses of 13 and 16 mg/kg/day compared to the start of the
treatment (Figure 4). During phenobarbitone therapy at a dose of 16 mg/kg/day in
a total of 8 dogs (53%) ALT was above referent values.
AP activities increased as phenobarbitone dose increased. Besides, the AP
activity levels in the first group of dogs significantly increased (p<0.01) at
16 mg/kg/day phenobarbitone (Figure 1). Same as for the first group of dogs, the
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Figure 3. Average blood serum AP activities (X ± SD) in the second group of dogs treated
with different phenobarbitone doses
*Significant difference (p<0.05) compared to measurements before treatment
**Very significant difference (p<0.01) compared to measurements before treatment
Figure 4. Average blood serum ALT activities (X ± SD) in the second group of dogs treated
with different phenobarbitone doses
*Significant difference (p<0.05) compared to measurements before treatment









second group had an increasing trend in AP activities with increasing
phenobarbitone doses. Two of the dogs from the second group with high AP
values were lethargic, weak, disoriented and with poor appetite. One of these two
dogs had an obviously enlarged abdomen.
The AP activity in the blood serum of dogs treated with phenobarbitone is
highly individual which is clearly shown by the large differences between the
activity levels. The obtained variations are in accordance to the existing published
data (Foster et al., 2000).
A number of authors states that phenobarbitone application in dogs results
in increased serum AP and ALT activities which are not accompanied by clinical
signs of liver disease (Fanuel-Barret and Vivier, 1993; Chauvet et al., 1995; Center,
1995; Booth, 1996; Dowling, 1999; Müller et al., 2000; Foster et al., 2001; Aitken et
al., 2003). In support of this finding are the results of our study with the difference
that in the group of dogs suffering from idiopathic epilepsy after treatment with
16 mg/kg/day phenobarbitone two dogs had clinical symptoms of hepatotoxicity.
AP activity in the dog number 11 was 1112 U/L and ALT activity was 292 U/L. For
the dog number 14 AP and ALT activities were 745 U/L and 134 U/L, respectively.
In these dogs a concurrent increase in AST values was registered, also (Figure 7).
The true reasons for such an increase in serum AP and ALT activities during
phenobarbitone therapy are still unclear. Results of previous studies indicate that
the explanation for such an increase may be the induction of enzymes which
results in increased concentrations of izoenzymes L-AP and C-AP within the
hepatocytes and their subsequent release in the general circulation (Solter and
Hoffmann, 1995; Deng et al., 1996). In support of this theory is a paper (Gaskill et
al., 2004) which claims that a significant increase in serum AP during
phenobarbitone therapy is the result of increased activities of all three isoenzymes
(C-AP, L-AP and B-AP).
The results published in this paper relative to AST activity in the first group of
treated dogs support the hypothesis which claims that phenobarbitone does not
induce enzymatically AST (Tettenborn et al., 1973; Müller et al., 2000). However,
the second group of dogs during treatment with 16 mg/kg/day phenobarbitone a
total of 5 dogs (33%) had increased AST activities which were above the starting
physiological referent values (Figure 5).
Two of the dogs with the highest AST values (111 U/L and 78 U/L) developed
clinical symptoms of liver disease. During liver disease AST increases paralell to
the activity of ALT (Center, 1995) which is in accordance to our finding in dogs
suffering from hepatotoxicity. Studies on the diagnostic value of different liver
enzymes in dogs with diagnosed liver disease indicate that an increase in serum
AST is a more sensitive diagnostic tool compared to serum ALT activity
(Abdeldaker and Hauge, 1986).
In the first group of dogs the significant decrease in albumin and total
protein concentrations was of a transient nature as it was recorded only in the third
week of the trial at 16 mg/kg/day phenobarbitone. The measured concentrations
of albumins and total proteins in the first group were within the reference values
and were independent of the duration of the phenobarbitone treatment.
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In the second group of dogs suffering from idiopathic epilepsy a decreasing
trend in albumin (Figure 6) and total protein concentrations (Figure 7) dependant
on phenobarbitone concentration was reported. This decrease was statistically
significant for phenobarbitone doses of 13 and 16 mg/kg/day. Albumin
concentrations lower than the reference values were measured in two dogs
treated with 16 mg/kg/day and low protein concentrations were measured in two
dogs treated with 13 mg/kg/day phenobarbitone and two dogs treated with
16 mg/kg/day of the same drug. The results obtained in our study are close to the
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Figure 5. Average blood serum AST activities (X ± SD) in the second group of dogs treated
with different phenobarbitone doses
*Significant difference (p<0.05) compared to measurements before treatment
Figure 6. Average blood serum albumin concentrations (X ± SD) in the second group of
dogs treated with different phenobarbitone doses







results published by Müller et al. (2000) and Aitken et al. (2003) contrary to the
findings of Foster et al. (2000) who reported the lack of a significant influence of
phenobarbitone dose on albumin and total protein concentrations. Serum
albumin concentration is often used as a non specific marker for hepatic function
(Center, 1995). Serum albumin concentrations below physiological values in
phenobarbitone treated dogs are probably the result of its direct influence on
albumin synthesis and/or its degradation (Mülleri et al., 2000). It is considered that
albumin levels below physiological values are the result of induced hepatic
dysfunction (Chauvet et al., 1995). This can be the rationale for our results as in
the second group in two dogs hepatotoxicity was diagnosed. This is supported by
the findings of Dayrell-Hart et al. (1991), as well. Transient falls in serum albumin
concentrations during phenobarbitone therapy have no major clinical importance
(Müller et al., 2000).
The short-lived statistically significant increase in triglyceride and
cholesterol concentrations was determined in the first group of dogs during two
measurements. However, no correlation between triglyceride and cholesterol
concentrations and phenobarbitone dose and therapy duration was established.
A cholesterol concentration below reference values was measured in one dog
suffering from idiopathic epilepsy.
A cholesterol concentration below reference values was measured in one
dog suffering from idiopathic epilepsy. This patient was treated with 16 mg/kg/day
phenobarbitone and displayed clinical symptoms of idiopathic epilepsy. As
cholesterol is synthetized in the liver the measured low concentration can be the
result of the hepatic disfunction caused by phenobarbitone (Chauvet et al., 1995).
All measured serum total bilirubin concentrations in the first group were
within the reference values and were not significantly different from the values
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Figure 7. Average blood serum total protein concentrations (X ± SD) in the second group
of dogs treated with different phenobarbitone doses









measured before treatment. There was no link between the concentration of total
bilirubin and time and dose of applied phenobarbitone. However, in the second
experimental group a statistically significant increase in plasma total bilirubin was
measured in dogs treated with 16 mg/kg/day phenobarbitone (Figure 8). The
concentration of total bilirubin did not change depending on dose or duration of
the treatment (Chauvet et al., 1995; Foster et al., 2000).
Measurements above referent values for total bilirubin can be the result of
phenobarbitone hepatotoxicity (Dayrell -Hart et al., 1991) or as an artifact due to
lipemic serum samples (Willard and Twedt, 1994; Burkhard and Meyer, 1995).
This was registered in two dogs treated with 16 mg/kg/day phenobarbitone and
suffering from hepatotoxicity had readings for plasma bilirubin above the
reference values.
Glucose concentration did not significantly change depending on
phenobarbitone dose or duration of treatment. All glucose measurements were
well within the physiological range in both experimental groups.
No relationship between phenobarbitone treatment and blood urea and
creatinine concentration was established. The transient statistically significant
difference in urea and creatinine concentration during one sampling was of no
clinical significance.
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Figure 8. Average blood serum total bilirubin (X ± SD) in the second group of dogs treated
with different phenobarbitone doses
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BIOHEMIJSKE PROMENE U KRVNOM SERUMU PASA TRETIRANIH
FENOBARBITONOM
ANDRI] N, POPOVI] N, STEPANOVI] P, FRANCUSKI JELENA i \UR\EVI] D
SADR@AJ
Iako ozna~en kao antiepileptik prvog izbora i veoma bezbedan lek, u litera-
turi su prezentovani razli~iti podaci o uticaju fenobarbitona na vrednosti bio-
hemijskih parametara krvnog seruma kod pasa. S obzirom na to, cilj ovog is-
tra`ivanja bio je da se ispita uticaj fenobarbitona pri razli~itim per os dozama na
vrednosti biohemijskih parametara krvnog seruma kod pasa, tokom kratkotrajne i
dugotrajne aplikacije. Istra`ivanje je sprovedeno na 30 pasa razli~itih rasa, oba
pola, starosne kategorije od dve do osam godina, od kojih su 15 bili zdravi psi a 15
psi oboleli od idiopatske epilepsije. Tokom kratkotrajne per os aplikacije fenobar-
bitona (intervali od po tri nedelje) zdravoj populaciji pasa pri razli~itim per os do-
zama, u krvnom serumu je registrovano zna~ajno pove}anje aktivnosti ALT i vrlo
zna~ajno pove}anje aktivnosti AP u zavisnosti od doze leka. Aplikacija fenobarbi-
tona u dozi od 16 mg/kg/dnevno tokom 14 nedelja zdravoj populaciji pasa uka-
zala je, na vrlo zna~ajno pove}anje aktivnosti ALT i AP u zavisnosti od du`ine tra-
janja aplikacije. Tokom hroni~ne aplikacije fenobarbitona psima obolelim od idio-
patske epilepsije, ustanovljeno je statisti~ki vrlo zna~ajno pove}anje aktivnosti AP
i ALT u krvnom serumu u zavisnosti od doze leka. Kod dve jedinke u bolesnoj
grupi pasa pri visokim terapeutskim dozama fenobarbitona registrovana je hepa-
totoksi~nost, {to je dovelo do statisti~ki zna~ajnog smanjenja koncentracije albu-
mina i ukupnih proteina, statisti~ki zna~ajnog pove}anja koncentracije ukupnog
bilirubina, statisti~ki zna~ajnog pove}anja aktivnosti AST i statisti~ki vrlo zna~aj-
nog pove}anja aktivnosti ALT i AP u krvnom serumu Dobijeni rezultati ukazuju da
dugotrajna aplikacija fenobarbitona, pri visokim terapeutskim dozama mo`e izaz-
vati hepatotoksi~nost. Nije ustanovljeno postojanje veze izme|u koncentracije
glukoze, uree, kreatinina, ukupnih proteina, albumina, ukupnog bilirubina, trigli-
cerida i holesterola u krvnom serumu pasa sa per os dozom fenobarbitona, niti sa
du`inom trajanja terapije.
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